Depression severity: early phase (2 weeks, range 1–4 weeks) Follow‐up: range 1–4 weeks
Strattera (atomoxetine) is the first non-stimulant drug approved by the Food and Drug Administration (FDA) to treat attention deficit hyperactivity disorder (ADHD) in adults and children over age 6
Atomoxetine is a non-stimulant ADHD medication that alters the brain's chemistry over a short period (about four weeks), which is similar to most antidepressants
For some, this medication has proven to be effective
The relationship between suicidal ideation and medications including antidepressants and atomoxetine remain unclear
Atomoxetine has an average rating of 7
It belongs to the group of medicines called selective norepinephrine reuptake inhibitors (SNRIs)
right upper stomach pain or tenderness
Some side effects may occur that usually do not need medical attention
Wellbutrin has an average rating of 6
In 176 pediatric patients with ADHD and comorbid anxiety disorders, 12 weeks of atomoxetine appeared to be more efficacious as a treatment for ADHD symptoms vs
001 Atomoxetine, the active ingredient in Strattera, is the best known nonstimulant medication to treat ADHD
Clinical practice guidelines (CPGs) on depression generally recommend treatment with an antidepressant for moderate to severe episodes of depression as one treatment option and, given the clinical situation, the treatment is recommended to stop after a certain period
Conservative switching strategies involve gradually tapering the first antidepressant followed by an
Atomoxetine is a noradrenaline reuptake inhibitor that was first approved in 2002 in the USA for treating ADHD
Atomoxetine can increase the adverse cardiovascular effects of tricyclic antidepressants if co-administered